Monopar Therapeutics Inc. (MNPR) Misses Q4 EPS by 1c

Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q4 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print